Bausch Health Companies (BHC) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Takeda Pharmaceutical (TAK) has outperformed Bausch Health Companies (BHC) over the past year, gaining 29.4% versus a loss of 4.7%. Over five years, TAK leads with a +31.3% price change compared with -78.8% for BHC. Takeda Pharmaceutical is the larger company by market cap ($59.16 billion vs $2.26 billion), about 26.2 times the size.
On valuation, Bausch Health Companies trades at a lower forward P/E (1.4x vs 34.9x for Takeda Pharmaceutical). Takeda Pharmaceutical pays a dividend yielding 1079.91%, while Bausch Health Companies does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | TAK |
|---|---|---|
| Share price | $6.04 | $18.52 |
| Market cap | $2.26B | $59.16B |
| 1-day change | -1.79% | +0.82% |
| YTD return | -13.09% | +18.79% |
| 1-year return | -4.73% | +29.42% |
| 5-year return | -78.80% | +31.35% |
| Forward P/E | 1.44 | 34.94 |
| EPS (TTM) | $-2.95 | $-0.34 |
| Dividend yield | 0.00% | 1079.91% |
| Annual dividend | $0.00 | $200.00 |
| Revenue (latest FY) | $10.27B | — |
| Revenue growth (YoY) | +6.66% | — |
| Net income (latest FY) | $157.00M | — |
| Operating margin | 17.66% | — |
| Net margin | 1.53% | — |
| 52-week high | $8.00 | $19.10 |
| 52-week low | $4.33 | $12.99 |
| Distance from 52-week high | -24.50% | -3.04% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +24.17% | +18.57% |
| Average volume | 3.24M | 3.04M |
| Shares outstanding | 373.99M | 3.19B |
| Employees | 20,300 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Takeda Pharmaceutical is about 26.2 times larger than Bausch Health Companies by market value ($59.16B vs $2.26B).
- TAK has outperformed BHC by 34.2 percentage points over the past year.
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (1079.91% vs 0.00%).
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
BHC vs TAK FAQ
Which is bigger, Bausch Health Companies or Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) is larger, with a market capitalization of $59.16B compared with $2.26B for Bausch Health Companies (BHC).
Which stock has performed better over the past year, BHC or TAK?
TAK returned +29.42% over the past 12 months, compared with -4.73% for BHC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Bausch Health Companies or Takeda Pharmaceutical?
Takeda Pharmaceutical pays a dividend yielding 1079.91%, while Bausch Health Companies does not currently pay a regular dividend.
Are Bausch Health Companies and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.